Latest news
Envudeucitinib Achieves 54% PASI 100 Rate at 48 Weeks in Phase 3 Extension - Dermatology TimesDermatology Times · Tue, 11 Aug 2026 18:56:42 GMTLong-term Data: Envudeucitinib Leads Oral Psoriasis Therapies in PASI-100 Skin Clearance - The Dermatology DigestThe Dermatology Digest · Tue, 11 Aug 2026 14:45:20 GMTAlumis reports strong Phase 3 data for envudeucitinib - TipRanksTipRanks · Mon, 10 Aug 2026 22:18:20 GMTAlumis: Envudeucitinib Shows 54% PASI 100 at 48 Weeks, NDA on Track for 4Q 2026 - TradingViewTradingView · Mon, 10 Aug 2026 20:14:34 GMTEnvudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies - The Manila TimesThe Manila Times · Mon, 10 Aug 2026 20:09:46 GMT